TP53 and ovarian carcinoma: Because the gene therapy construct being developed by our lab is a p53-BH3 fusion construct, ovarian cancer cells were chosen for their varying p53 statuses: p53 null, p53 dominant negative (DN) mutant, and p53 DN/aggregation mutant for Skov3 [23], Ovcar3 [23], and Kuramochi [32], respectively.